title: [Cancer and deep venous thrombosis: the purpose of the CATCH clinical trial].
abstract: Cancer has the potential to induce hypercoagulable states. On the other hand, venous thromboembolism may be the harbinger of an occult cancer, may represent a complication of known malignant disease or complicate hospitalization, surgery or various systemic treatments. The importance of venous thromboembolism in patients with cancer is often underestimated resulting in under-diagnosis, which may lead to significant morbidity and mortality. However, many cancer patients do not receive prophylaxis and suitable treatment for venous thromboembolism. The author make some considerations on this disease by addressing the interest and the objectives of the clinical trial CATCH and use of sodium tinzaparin.
authors.affiliation: Serviço de Oncologia Médica, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, & Instituto Português de Oncologia, Porto, Portugal.
authors.forename: António
authors.initials: A
authors.lastname: Araújo
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D016032:Randomized Controlled Trials as Topic; D000078222:Tinzaparin; D020246:Venous Thrombosis / Q000209:etiology* / Q000517:prevention & control; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D014859:Warfarin; D000078222:Tinzaparin